Literature DB >> 9658731

Classification and diagnosis of iron overload.

A Piperno1.   

Abstract

BACKGROUND AND
OBJECTIVE: Iron overload is the result of many disorders and could lead to the development of organ damage and increased mortality. The recent description of new conditions associated with iron overload and the identification of the genetic defect of hereditary hemochromatosis prompted us to review this subject and to redefine the diagnostic criteria of iron overload disorders. EVIDENCE AND INFORMATION SOURCES: The material examined in the present review includes articles published in the Journals covered by the Science Citation Index and Medline. The author has been working in the field of iron overload diseases for several years and has contributed ten of the papers cited in the references. STATE OF THE ART AND PERSPECTIVES: Iron overload can be classified on the basis of different criteria: route of access of iron within the organism, predominant tissue site of iron accumulation and cause of the overload. Excess iron can gain access by the enteral route, the parenteral route, and placental route during fetal life. The different distribution of iron within parenchymal or reticuloendothelial storage areas indicates different pathogenetic mechanisms of iron accumulation and has relevant implications in terms of organ damage and prognosis of the patients. Iron overload may be either primary, resulting from a deregulation of intestinal iron absorption as in hemochromatosis or secondary to other congenital or acquired conditions. Diagnosis of iron overload can be suspected on the basis of clinical data, high transferrin saturation and/or serum ferritin values. However, several hyperferritinemic conditions are not related to iron overload, but may imply severe disorders (inflammations, neoplasia) or a deregulation of ferritin synthesis (hereditary hyperferritinemia-cataract syndrome), and iron overload secondary to aceruloplasminemia, and the recently described dysmetabolic-associated liver iron overload syndrome, are characterized by low or normal transferrin saturation levels. Liver biopsy is still very useful in the diagnostic approach to iron overload disorders, by defining the amount and the distribution of iron within the liver. The analysis of HFE gene mutations (C282Y and H63D) is a simple and strong tool in the diagnostic work out of iron overload conditions.

Entities:  

Mesh:

Year:  1998        PMID: 9658731

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  32 in total

1.  Ferroportin mutation in autosomal dominant hemochromatosis: loss of function, gain in understanding.

Authors:  R E Fleming; W S Sly
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

2.  Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease.

Authors:  James E Nelson; Laura Wilson; Elizabeth M Brunt; Matthew M Yeh; David E Kleiner; Aynur Unalp-Arida; Kris V Kowdley
Journal:  Hepatology       Date:  2010-11-29       Impact factor: 17.425

3.  Hyperferritinaemia without iron overload in a blood donor.

Authors:  Domenico Testa; Silvia Tavera
Journal:  Blood Transfus       Date:  2010-09-03       Impact factor: 3.443

4.  CYBRD1 as a modifier gene that modulates iron phenotype in HFE p.C282Y homozygous patients.

Authors:  Sara Pelucchi; Raffaella Mariani; Stefano Calza; Anna Ludovica Fracanzani; Giulia Litta Modignani; Francesca Bertola; Fabiana Busti; Paola Trombini; Mirella Fraquelli; Gian Luca Forni; Domenico Girelli; Silvia Fargion; Claudia Specchia; Alberto Piperno
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

5.  MRI-based R2* mapping in patients with suspected or known iron overload.

Authors:  Emre Aslan; Jack W Luo; An Lesage; Philippe Paquin; Milena Cerny; Anne Shu-Lei Chin; Damien Olivié; Guillaume Gilbert; Denis Soulières; An Tang
Journal:  Abdom Radiol (NY)       Date:  2021-01-02

6.  A male patient with ferroportin disease B and a female patient with iron overload similar to ferroportin disease B.

Authors:  Tetsuji Yamashita; Natsuko Morotomi; Tetsuro Sohda; Hisao Hayashi; Naohiko Yoshida; Keiko Ochi; Izumi Ohkura; Mika Karita; Hiroko Fujiwara; Haruhiko Yamashita; Ai Hattori; Yasuaki Tatsumi
Journal:  Clin J Gastroenterol       Date:  2014-04-19

7.  [Rust-colored conjunctival and sub-conjunctival discolorations : Differential diagnosis of conjunctival melanosis].

Authors:  J Rueckel; C Auw-Hädrich; T Reinhard; P Eberwein
Journal:  Ophthalmologe       Date:  2018-12       Impact factor: 1.059

8.  Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.

Authors:  Maria Domenica Cappellini; John Porter; Amal El-Beshlawy; Chi-Kong Li; John F Seymour; Mohsen Elalfy; Norbert Gattermann; Stéphane Giraudier; Jong-Wook Lee; Lee Lee Chan; Kai-Hsin Lin; Christian Rose; Ali Taher; Swee Lay Thein; Vip Viprakasit; Dany Habr; Gabor Domokos; Bernard Roubert; Antonis Kattamis
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

9.  The Association between Serum Ferritin Level, Tissue Doppler Echocardiography, Cardiac T2* MRI, and Heart Rate Recovery in Patients with Beta Thalassemia Major.

Authors:  Isa Oner Yuksel; Erkan Koklu; Erdal Kurtoglu; Sakir Arslan; Goksel Cagirci; Volkan Karakus; Gorkem Kus; Serkan Cay; Selcuk Kucukseymen
Journal:  Acta Cardiol Sin       Date:  2016-03       Impact factor: 2.672

10.  Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.

Authors:  Ali Taher; Amal El-Beshlawy; Mohsen S Elalfy; Kusai Al Zir; Shahina Daar; Dany Habr; Ulrike Kriemler-Krahn; Abdel Hmissi; Abdullah Al Jefri
Journal:  Eur J Haematol       Date:  2009-01-28       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.